论文部分内容阅读
目的探究低分子肝素联合无创通气治疗肺源性心脏病(肺心病)急性加重期的效果。方法 150例肺心病急性加重期患者为研究对象,随机分成对照组和观察组,各75例。对照组给予无创通气治疗,观察组给予低分子肝素联合无创通气治疗。对比两组患者的血气指标[动脉血氧分压(PaO_2)、动脉血二氧化碳分压(PaCO_2)]和治疗效果。结果治疗前,两组患者的PaO_2、PaCO_2对比,差异均无统计学意义(P>0.05);治疗后,两组患者的PaO_2、PaCO_2均较治疗前改善,且观察组改善幅度大于对照组,差异均具有统计学意义(P<0.05)。观察组患者总有效率97.33%高于对照组88.00%,差异具有统计学意义(χ~2=4.807,P<0.05)。结论低分子肝素联合无创通气用于肺心病急性加重期治疗的效果确切,有助于快速改善患者的通气状况,减轻症状,提高生活质量。
Objective To investigate the effect of low molecular weight heparin combined with non-invasive ventilation in the treatment of acute exacerbation of pulmonary heart disease (pulmonary heart disease). Methods A total of 150 patients with acute exacerbation of pulmonary heart disease were randomly divided into control group and observation group, with 75 cases in each. The control group was given non-invasive ventilation, and the observation group was given low molecular weight heparin combined with noninvasive ventilation. Blood gas indexes (PaO_2, PaCO_2) and therapeutic effects were compared between the two groups. Results Before treatment, there was no significant difference in the PaO_2 and PaCO_2 between the two groups (P> 0.05). After treatment, the PaO_2 and PaCO_2 in both groups were improved compared with those before treatment, and the improvement in the observation group was greater than that in the control group. The differences were statistically significant (P <0.05). The total effective rate in observation group was 97.33% higher than 88.00% in control group, the difference was statistically significant (χ ~ 2 = 4.807, P <0.05). Conclusion Low molecular weight heparin combined with noninvasive ventilation is effective in the treatment of acute exacerbation of pulmonary heart disease, which can help to rapidly improve the ventilation, alleviate the symptoms and improve the quality of life.